Medical College of Wisconsin
CTSIResearch InformaticsREDCap

Stuart J. Wong MD

Stuart J. Wong MD profile photo picture

Center Director, Professor

Institution: Medical College of Wisconsin
Department: Medicine
Division: Medicine Hematology Oncology

Member of the Cancer Center
Member of the Center for Disease Prevention Research (CDPR)
Member of the Center for Immunology

View Curriculum Vitae

Publications (64)

  • Multiomic Selection of Cancer-Testis Antigens as Precision Immuno-oncologic Targets in Head and Neck Cancer. (Memon AA, Awan MJ, Espinosa OV, Kuehn R, Frei A, Foeckler J, Bruening J, Akakpo K, Massey B, Stadler M, Wong S, Himburg HA, Zenga J) JAMA Otolaryngol Head Neck Surg 2025 Dec 01;151(12):1196-1207 PMID: 41129177 PMCID: PMC12550742 SCOPUS ID: 2-s2.0-105022204542 10/23/2025    
  • Tumoral Skin Invasion Is an Independent Predictor of Rapid Recurrence in Head and Neck Cancer. (Memon AA, Khalil M, Espinosa OV, Said I, Yang E, Adams JA, Friedland DR, Khani M, Luo J, Kuehn R, Frei A, Foeckler J, Akakpo K, Massey B, Stadler M, Wong S, Himburg HA, Awan MJ, Bruening J, Zenga J) Head Neck 2026 Feb;48(2):535-542 PMID: 41054923 SCOPUS ID: 2-s2.0-105018525815 10/07/2025    
  • Efficacy and safety of one-time autologous tumor-infiltrating lymphocyte cell therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. (Ferris RL MD,, Leidner RS, Chung CH, Jimeno A, Lee SM, Sukari A, Nieva JJ, Grilley-Olson JE, Redman R, Wong SJ, Villaflor VM, Misleh J, Finckenstein FG, Chou J, Gastman B, Fiaz R, Catlett M, Yi M, Cohen EEW) J Immunother Cancer 2025 Aug 24;13(8) PMID: 40854613 PMCID: PMC12382571 SCOPUS ID: 2-s2.0-105014348606 08/28/2025       3 Citations
  • Phase II Study of Low-Dose Paclitaxel and Cisplatin in Combination With Split-Course Concomitant Twice-Daily Reirradiation in Recurrent Squamous Cell Carcinoma of the Head and Neck: Long-term Follow-up of NRG Oncology RTOG 9911. (Langer CJ, Harris J, Horwitz EM, Kies M, Ad VB, Wong SJ, Caudell JJ, Zeitzer KL, Spencer SA, Zhang Q, Yom SS, Le QT) Int J Radiat Oncol Biol Phys 2026 Jan 01;124(1):50-60 PMID: 40752652 PMCID: PMC12790980 SCOPUS ID: 2-s2.0-105014126635 08/03/2025       1 Citation
  • Re-examining post-operative chemoradiotherapy in head and neck cancer: an updated long-term combined analysis of RTOG 9501/EORTC 22931. (Zumsteg ZS, Luu M, Fortpied C, Jang JK, Chen MM, Mallen-St Clair J, Walgama E, Le QT, Machtay M, Tribius S, Forastiere A, Wong S, Ozsahin EM, Gregoire V, Vermorken JB, Ho AS, Yom SS) Ann Oncol 2025 Nov;36(11):1379-1388 PMID: 40680992 PMCID: PMC12376881 SCOPUS ID: 2-s2.0-105013550806 07/19/2025       3 Citations
  • Radiation therapy results in preferential tumor antigen-specific lymphodepletion in head and neck cancer. (Zenga J, Awan MJ, Frei A, Foeckler J, Kuehn R, Kasprzak J, Massey B, Bruening J, Akakpo K, Shukla M, Wong SJ, Mathison AJ, Wendt Andrae J, Hunt B, Puzyrenko A, Jin VX, Memon AA, Villarreal Espinosa O, Chen F, Shaheduzzaman M, Kearl T, Hematti P, Himburg HA) Nat Commun 2025 Jul 01;16(1):5660 PMID: 40593620 PMCID: PMC12219838 SCOPUS ID: 2-s2.0-105009625716 07/02/2025       4 Citations
  • Re-examining Post-operative Chemoradiotherapy in Head and Neck Cancer: An Updated Long-Term Combined Analysis of RTOG 9501/EORTC 22931 (Z.S. Zumsteg 1, M. Luu 2, C. Fortpied 3, J.K. Jang 1, M.M. Chen 4, J. Mallen-St. Clair 5, E. Walgama 5, Q.T. Le 6, M. Machtay 7, S. Tribius 8, A. Forastiere 9, S. Wong 10, E. Mahmut Ozsahin 11, V. Gregoire 12, J.B. Vermorken 13, A.S. Ho 6, S.S. Yom 14) Annals of Oncology 05/29/2025    
  • Quantitative magnetic resonance imaging responses in head and neck cancer patients treated with magnetic resonance-guided hypofractionated radiation therapy. (Bonate R, Awan MJ, Himburg HA, Wong S, Shukla M, Tarima S, Zenga J, Paulson ES) Phys Imaging Radiat Oncol 2025 Jan;33:100693 PMID: 39877149 PMCID: PMC11772986 SCOPUS ID: 2-s2.0-85214566416 01/29/2025       2 Citations
  • Quantitative magnetic resonance imaging responses in head and neck cancer patients treated with magnetic resonance-guided hypofractionated radiation therapy (Bonate R, Awan MJ, Himburg HA, Wong S, Shukla M, Tarima S, Zenga J, Paulson ES) Physics and Imaging in Radiation Oncology January 2025;33 SCOPUS ID: 2-s2.0-85214566416 01/01/2025       2 Citations
  • Type I interferon signaling promotes radioresistance in head and neck cancer. (Zenga J, Awan MJ, Frei A, Massey B, Bruening J, Shukla M, Sharma GP, Shreenivas A, Wong SJ, Zimmermann MT, Mathison AJ, Himburg HA) Transl Cancer Res 2024 May 31;13(5):2535-2543 PMID: 38881922 PMCID: PMC11170510 SCOPUS ID: 2-s2.0-85195040296 06/17/2024       5 Citations
  • Intensity-Modulated Reirradiation Therapy With Nivolumab in Recurrent or Second Primary Head and Neck Squamous Cell Carcinoma: A Nonrandomized Controlled Trial. (Saba NF, Wong SJ, Nasti T, McCook-Veal AA, McDonald MW, Stokes WA, Anderson AM, Ekpenyong A, Rupji M, Abousaud M, Rudra S, Bates JE, Remick JS, Joshi NP, Woody NM, Awan M, Geiger JL, Shreenivas A, Samsa J, Ward MC, Schmitt NC, Patel MR, Higgins KA, Teng Y, Steuer CE, Shin DM, Liu Y, Ahmed R, Koyfman SA) JAMA Oncol 2024 Jul 01;10(7):896-904 PMID: 38780927 PMCID: PMC11117153 SCOPUS ID: 2-s2.0-85194249090 05/23/2024       9 Citations
  • De-Escalation After DE-ESCALATE and RTOG 1016: A Head and Neck Cancer InterGroup Framework for Future De-Escalation Studies. (Mehanna H, Rischin D, Wong SJ, Gregoire V, Ferris R, Waldron J, Le QT, Forster M, Gillison M, Laskar S, Tahara M, Psyrri A, Vermorken J, Porceddu S) J Clin Oncol 2020 Aug 01;38(22):2552-2557 PMID: 32496903 PMCID: PMC7392745 SCOPUS ID: 2-s2.0-85089129881 06/05/2020       75 Citations
  • Intermediate-grade carcinoma of the parotid and the impact of adjuvant radiation (North L, Stadler M, Massey B, Campbell B, Shukla M, Awan M, Schultz CJ, Shreenivas A, Wong S, Graboyes E, Pipkorn P, Zenga J) American Journal of Otolaryngology Head and Neck Medicine and Surgery November - December 2019;40(6) SCOPUS ID: 2-s2.0-85071985153 11/01/2019       13 Citations
  • Lymph node yield, depth of invasion, and survival in node-negative oral cavity cancer. (Zenga J, Divi V, Stadler M, Massey B, Campbell B, Shukla M, Awan M, Schultz CJ, Shreenivas A, Wong S, Jackson RS, Pipkorn P) Oral Oncol 2019 Nov;98:125-131 PMID: 31586894 SCOPUS ID: 2-s2.0-85072773115 10/07/2019       29 Citations
  • Intermediate-grade carcinoma of the parotid and the impact of adjuvant radiation. (North L, Stadler M, Massey B, Campbell B, Shukla M, Awan M, Schultz CJ, Shreenivas A, Wong S, Graboyes E, Pipkorn P, Zenga J) Am J Otolaryngol 2019;40(6):102282 PMID: 31519432 SCOPUS ID: 2-s2.0-85071985153 09/15/2019       13 Citations
  • Nomogram to Predict the Benefit of Intensive Treatment for Locoregionally Advanced Head and Neck Cancer. (Mell LK, Shen H, Nguyen-Tân PF, Rosenthal DI, Zakeri K, Vitzthum LK, Frank SJ, Schiff PB, Trotti AM 3rd, Bonner JA, Jones CU, Yom SS, Thorstad WL, Wong SJ, Shenouda G, Ridge JA, Zhang QE, Le QT) Clin Cancer Res 2019 Dec 01;25(23):7078-7088 PMID: 31420360 PMCID: PMC7028339 SCOPUS ID: 2-s2.0-85074493938 08/20/2019       25 Citations
  • Lymph node yield from neck dissection in HPV-associated oropharyngeal cancer. (Zenga J, Stadler M, Massey B, Campbell B, Shukla M, Awan M, Schultz CJ, Wong S, Jackson RS, Pipkorn P) Laryngoscope 2020 Mar;130(3):666-671 PMID: 31206708 SCOPUS ID: 2-s2.0-85067854046 06/18/2019       18 Citations
  • Validation of NRG oncology/RTOG-0129 risk groups for HPV-positive and HPV-negative oropharyngeal squamous cell cancer: Implications for risk-based therapeutic intensity trials. (Fakhry C, Zhang Q, Gillison ML, Nguyen-Tân PF, Rosenthal DI, Weber RS, Lambert L, Trotti AM 3rd, Barrett WL, Thorstad WL, Yom SS, Wong SJ, Ridge JA, Rao SSD, Spencer S, Fortin A, Raben D, Harris J, Le QT) Cancer 2019 Jun 15;125(12):2027-2038 PMID: 30913305 PMCID: PMC6594017 SCOPUS ID: 2-s2.0-85063458690 03/27/2019       67 Citations
  • Prophylactic Cranial Irradiation vs Observation in Patients With Locally Advanced Non-Small Cell Lung Cancer: A Long-term Update of the NRG Oncology/RTOG 0214 Phase 3 Randomized Clinical Trial. (Sun A, Hu C, Wong SJ, Gore E, Videtic G, Dutta S, Suntharalingam M, Chen Y, Gaspar LE, Choy H) JAMA Oncol 2019 Jun 01;5(6):847-855 PMID: 30869743 PMCID: PMC6459052 SCOPUS ID: 2-s2.0-85062993057 03/15/2019       64 Citations
  • Salvage of Recurrence after Surgery and Adjuvant Therapy: A Multi-institutional Study. (Zenga J, Graboyes E, Janz T, Drake V, Rettig E, Desai S, Nickel C, Shabani S, Padhya T, Scarpinato M, Stadler M, Massey B, Campbell B, Shukla M, Awan M, Schultz CJ, Wong S, Jackson RS, Pipkorn P) Otolaryngol Head Neck Surg 2019 Jul;161(1):74-81 PMID: 30753110 SCOPUS ID: 2-s2.0-85061834834 02/13/2019       23 Citations
  • Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy. (Zandberg DP, Algazi AP, Jimeno A, Good JS, Fayette J, Bouganim N, Ready NE, Clement PM, Even C, Jang RW, Wong S, Keilholz U, Gilbert J, Fenton M, Braña I, Henry S, Remenar E, Papai Z, Siu LL, Jarkowski A, Armstrong JM, Asubonteng K, Fan J, Melillo G, Mesía R) Eur J Cancer 2019 Jan;107:142-152 PMID: 30576970 SCOPUS ID: 2-s2.0-85058541688 12/24/2018       236 Citations
  • E3611-A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon-α2b in Advanced Melanoma. (Tarhini AA, Lee SJ, Li X, Rao UNM, Nagarajan A, Albertini MR, Mitchell JW Jr, Wong SJ, Taylor MA, Laudi N, Truong PV, Conry RM, Kirkwood JM) Clin Cancer Res 2019 Jan 15;25(2):524-532 PMID: 30420448 PMCID: PMC6335150 SCOPUS ID: 2-s2.0-85060063447 11/14/2018       9 Citations
  • In Regard to Bossi et al. (Fakhry C, Nguyen-Tân PF, Lambert L, Rosenthal DI, Weber RS, Gillison ML, Trotti AM 3rd, Barrett WL, Thorstad WL, Jones CU, Yom SS, Wong SJ, Ridge JA, Rao SSD, Bonner JA, Vigneault E, Raben D, Kudrimoti MR, Harris J, Le QT) Int J Radiat Oncol Biol Phys 2018 Nov 01;102(3):669-670 PMID: 30238902 SCOPUS ID: 2-s2.0-85053320936 09/22/2018       1 Citation
  • Reirradiation for Head and Neck Cancer: The Who and the How. (Margalit DN, Wong SJ) Int J Radiat Oncol Biol Phys 2018 Mar 01;100(3):618-620 PMID: 29413275 SCOPUS ID: 2-s2.0-85044236227 02/08/2018       11 Citations
  • Final results of a multi-institutional phase II trial of reirradiation with concurrent weekly cisplatin and cetuximab for recurrent or second primary squamous cell carcinoma of the head and neck. (Awan MJ, Nedzi L, Wang D, Tumati V, Sumer B, Xie XJ, Smith I, Truelson J, Hughes R, Myers LL, Lavertu P, Wong S, Yao M) Ann Oncol 2018 Apr 01;29(4):998-1003 PMID: 29346519 SCOPUS ID: 2-s2.0-85046676913 01/19/2018       22 Citations
  • Immune Checkpoint Inhibitor-Associated Type 1 Diabetes Mellitus: Case Series, Review of the Literature, and Optimal Management. (Kapke J, Shaheen Z, Kilari D, Knudson P, Wong S) Case Rep Oncol 2017;10(3):897-909 PMID: 29279690 PMCID: PMC5731100 SCOPUS ID: 2-s2.0-85031826225 12/28/2017       54 Citations
  • Development and Validation of Nomograms Predictive of Overall and Progression-Free Survival in Patients With Oropharyngeal Cancer. (Fakhry C, Zhang Q, Nguyen-Tân PF, Rosenthal DI, Weber RS, Lambert L, Trotti AM 3rd, Barrett WL, Thorstad WL, Jones CU, Yom SS, Wong SJ, Ridge JA, Rao SSD, Bonner JA, Vigneault E, Raben D, Kudrimoti MR, Harris J, Le QT, Gillison ML) J Clin Oncol 2017 Dec 20;35(36):4057-4065 PMID: 28777690 PMCID: PMC5736236 SCOPUS ID: 2-s2.0-85033804691 08/05/2017       129 Citations
  • Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis. (Lacas B, Bourhis J, Overgaard J, Zhang Q, Grégoire V, Nankivell M, Zackrisson B, Szutkowski Z, Suwiński R, Poulsen M, O'Sullivan B, Corvò R, Laskar SG, Fallai C, Yamazaki H, Dobrowsky W, Cho KH, Beadle B, Langendijk JA, Viegas CMP, Hay J, Lotayef M, Parmar MKB, Aupérin A, van Herpen C, Maingon P, Trotti AM, Grau C, Pignon JP, Blanchard P, MARCH Collaborative Group) Lancet Oncol 2017 Sep;18(9):1221-1237 PMID: 28757375 PMCID: PMC5737765 SCOPUS ID: 2-s2.0-85026328996 08/02/2017       304 Citations
  • The Not Knowing Is the Hardest Part. (Shukla ME, Wong SJ) Int J Radiat Oncol Biol Phys 2017 Apr 01;97(5):1051-1053 PMID: 28332988 SCOPUS ID: 2-s2.0-85015311714 03/24/2017    
  • Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic Alterations. (Wang K, Russell JS, McDermott JD, Elvin JA, Khaira D, Johnson A, Jennings TA, Ali SM, Murray M, Marshall C, Oldham DS, Washburn D, Wong SJ, Chmielecki J, Yelensky R, Lipson D, Miller VA, Stephens PJ, Serracino HS, Ross JS, Bowles DW) Clin Cancer Res 2016 Dec 15;22(24):6061-6068 PMID: 27334835 SCOPUS ID: 2-s2.0-85007020561 06/24/2016       116 Citations
  • Locoregional Recurrent or Second Primary Head and Neck Cancer: Management Strategies and Challenges. (Wong SJ, Heron DE, Stenson K, Ling DC, Vargo JA) Am Soc Clin Oncol Educ Book 2016;35:e284-92 PMID: 27249734 SCOPUS ID: 2-s2.0-85021848120 06/02/2016       31 Citations
  • Dual Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor 2 Inhibition in Squamous Cell Carcinoma of the Head and Neck; Is the Jury Still Out? (Saba NF, Wong SJ) J Clin Oncol 2016 Jun 10;34(17):2072-3 PMID: 27069073 SCOPUS ID: 2-s2.0-84971673823 04/14/2016       2 Citations
  • Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors. (Wong SJ, Karrison T, Hayes DN, Kies MS, Cullen KJ, Tanvetyanon T, Argiris A, Takebe N, Lim D, Saba NF, Worden FP, Gilbert J, Lenz HJ, Razak AR, Roberts JD, Vokes EE, Cohen EE) Ann Oncol 2016 Feb;27(2):318-23 PMID: 26598548 PMCID: PMC4722891 SCOPUS ID: 2-s2.0-84961620192 11/26/2015       84 Citations
  • Ex vivo antibody-dependent cellular cytotoxicity inducibility predicts efficacy of cetuximab. (Taylor RJ, Saloura V, Jain A, Goloubeva O, Wong S, Kronsberg S, Nagilla M, Silpino L, de Souza J, Seiwert T, Vokes E, Villaflor V, Cohen EE) Cancer Immunol Res 2015 May;3(5):567-74 PMID: 25769300 PMCID: PMC4681575 SCOPUS ID: 2-s2.0-84962277989 03/15/2015       43 Citations
  • Efficacy endpoints of radiation therapy group protocol 0247: a randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer. (Wong SJ, Moughan J, Meropol NJ, Anne PR, Kachnic LA, Rashid A, Watson JC, Mitchell EP, Pollock J, Lee RJ, Haddock M, Erickson BA, Willett CG) Int J Radiat Oncol Biol Phys 2015 Jan 01;91(1):116-23 PMID: 25446610 PMCID: PMC4385459 SCOPUS ID: 2-s2.0-84922975792 12/03/2014       33 Citations
  • EGFRvIII expression in squamous cell carcinoma of the skin. (Dziunycz PJ, Lazarova Z, Duncan N, Wong S, Neuburg M, Hofbauer GF, Olasz EB) JAMA Dermatol 2013 Oct;149(10):1240-2 PMID: 23986462 SCOPUS ID: 2-s2.0-84885940634 08/30/2013       11 Citations
  • A phase I trial of aminolevulinic acid-photodynamic therapy for treatment of oral leukoplakia. (Wong SJ, Campbell B, Massey B, Lynch DP, Cohen EEW, Blair E, Selle R, Shklovskaya J, Jovanovic BD, Skripkauskas S, Dew A, Kulesza P, Parimi V, Bergan RC, Szabo E) Oral Oncol 2013 Sep;49(9):970-976 PMID: 23845699 PMCID: PMC4456032 SCOPUS ID: 2-s2.0-84883087653 07/13/2013       30 Citations
  • Neoadjuvant versus induction chemotherapy: more than semantics. (Devisetty K, Wong SJ) J Clin Oncol 2013 Aug 10;31(23):2971-2 PMID: 23733777 SCOPUS ID: 2-s2.0-84889851222 06/05/2013       10 Citations
  • Statistical model for prediction of hearing loss in patients receiving cisplatin chemotherapy. (Johnson A, Tarima S, Wong S, Friedland DR, Runge CL) JAMA Otolaryngol Head Neck Surg 2013 Mar;139(3):256-64 PMID: 23429908 SCOPUS ID: 2-s2.0-84875829521 02/23/2013       15 Citations
  • Clinical regression of squamous cell carcinoma and keratoacanthomas in a patient treated with a hypomethylating agent. (Randhawa J, Wong S, Atallah E, Olasz E) Int J Dermatol 2014 Jan;53(1):e13-4 PMID: 22998756 SCOPUS ID: 2-s2.0-84890794842 09/25/2012       2 Citations
  • Diagnosis to treatment interval and outcome in patients with locally-advanced squamous cell carcinoma of the head and neck in a veterans affairs medical center (Brinkerhoff BT, Choong NW, Massey BL, Gore EM, Firat SY, Wong SJ, Campbell BH, Schapira RM, Visotcky AM, Tripp PM) Journal of Cancer Science and Therapy 2012;4(5):111-115 SCOPUS ID: 2-s2.0-84863219883 07/05/2012       7 Citations
  • Retreatment of recurrent head and neck cancer in a previously irradiated field. (Wong SJ, Bourhis J, Langer CJ) Semin Radiat Oncol 2012 Jul;22(3):214-9 PMID: 22687946 SCOPUS ID: 2-s2.0-84862137892 06/13/2012       13 Citations
  • Head and neck carcinoma in the United States: first comprehensive report of the Longitudinal Oncology Registry of Head and Neck Carcinoma (LORHAN). (Ang KK, Chen A, Curran WJ Jr, Garden AS, Harari PM, Murphy BA, Wong SJ, Bellm LA, Schwartz M, Newman J, Adkins D, Hayes DN, Parvathaneni U, Brachman D, Ghabach B, Schneider CJ, Greenberg M, Anné PR) Cancer 2012 Dec 01;118(23):5783-92 PMID: 22569917 SCOPUS ID: 2-s2.0-84869490978 05/10/2012       58 Citations
  • A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck. (de Souza JA, Davis DW, Zhang Y, Khattri A, Seiwert TY, Aktolga S, Wong SJ, Kozloff MF, Nattam S, Lingen MW, Kunnavakkam R, Stenson KM, Blair EA, Bozeman J, Dancey JE, Vokes EE, Cohen EE) Clin Cancer Res 2012 Apr 15;18(8):2336-43 PMID: 22371453 PMCID: PMC4467891 SCOPUS ID: 2-s2.0-84859873106 03/01/2012       110 Citations
  • Continuous-course reirradiation with concurrent carboplatin and paclitaxel for locally recurrent, nonmetastatic squamous cell carcinoma of the head-and-neck. (Kharofa J, Choong N, Wang D, Firat S, Schultz C, Sadasiwan C, Wong S) Int J Radiat Oncol Biol Phys 2012 Jun 01;83(2):690-5 PMID: 22112556 SCOPUS ID: 2-s2.0-84861097469 11/25/2011       40 Citations
  • Radiation Therapy Oncology Group 0247: a randomized Phase II study of neoadjuvant capecitabine and irinotecan or capecitabine and oxaliplatin with concurrent radiotherapy for patients with locally advanced rectal cancer. (Wong SJ, Winter K, Meropol NJ, Anne PR, Kachnic L, Rashid A, Watson JC, Mitchell E, Pollock J, Lee RJ, Haddock M, Erickson BA, Willett CG) Int J Radiat Oncol Biol Phys 2012 Mar 15;82(4):1367-75 PMID: 21775070 PMCID: PMC3208721 SCOPUS ID: 2-s2.0-84857921757 07/22/2011       73 Citations
  • How does TPF improve survival over PF? (Devisetty K, Wong SJ, Mell LK) Lancet Oncol 2011 May;12(5):419-20; author reply 421-2 PMID: 21536218 SCOPUS ID: 2-s2.0-79955460481 05/04/2011       3 Citations
  • Longitudinal Oncology Registry of Head and Neck Carcinoma (LORHAN): analysis of chemoradiation treatment approaches in the United States. (Wong SJ, Harari PM, Garden AS, Schwartz M, Bellm L, Chen A, Curran WJ, Murphy BA, Ang KK) Cancer 2011 Apr 15;117(8):1679-86 PMID: 21472715 SCOPUS ID: 2-s2.0-79953797936 04/08/2011       46 Citations
  • Comparison of physical examination and fluorodeoxyglucose positron emission tomography/computed tomography 4-6 months after radiotherapy to assess residual head-and-neck cancer. (Zundel MT, Michel MA, Schultz CJ, Maheshwari M, Wong SJ, Campbell BH, Massey BL, Blumin J, Wilson JF, Wang D) Int J Radiat Oncol Biol Phys 2011 Dec 01;81(5):e825-32 PMID: 21300450 SCOPUS ID: 2-s2.0-81855184909 02/09/2011       37 Citations
  • Phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small-cell lung cancer: primary analysis of radiation therapy oncology group study RTOG 0214. (Gore EM, Bae K, Wong SJ, Sun A, Bonner JA, Schild SE, Gaspar LE, Bogart JA, Werner-Wasik M, Choy H) J Clin Oncol 2011 Jan 20;29(3):272-8 PMID: 21135270 PMCID: PMC3056462 SCOPUS ID: 2-s2.0-79951964973 12/08/2010       262 Citations
  • Phase III trial of prophylactic cranial irradiation compared with observation in patients with locally advanced non-small-cell lung cancer: neurocognitive and quality-of-life analysis. (Sun A, Bae K, Gore EM, Movsas B, Wong SJ, Meyers CA, Bonner JA, Schild SE, Gaspar LE, Bogart JA, Werner-Wasik M, Choy H) J Clin Oncol 2011 Jan 20;29(3):279-86 PMID: 21135267 PMCID: PMC3056463 SCOPUS ID: 2-s2.0-79951963826 12/08/2010       330 Citations
  • Longitudinal oncology registry of head and neck carcinoma (LORHAN): initial supportive care findings. (Murphy BA, Chen A, Curran WJ Jr, Garden AS, Harari PM, Wong SJ, Ang KK) Support Care Cancer 2009 Nov;17(11):1393-401 PMID: 19263090 SCOPUS ID: 2-s2.0-70350173397 03/06/2009       11 Citations
  • Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. (Cohen EE, Davis DW, Karrison TG, Seiwert TY, Wong SJ, Nattam S, Kozloff MF, Clark JI, Yan DH, Liu W, Pierce C, Dancey JE, Stenson K, Blair E, Dekker A, Vokes EE) Lancet Oncol 2009 Mar;10(3):247-57 PMID: 19201650 PMCID: PMC2768532 SCOPUS ID: 2-s2.0-62349097073 02/10/2009       250 Citations
  • Reirradiation and concurrent chemotherapy after salvage surgery: pay now or pay later. (Wong SJ, Spencer S) J Clin Oncol 2008 Dec 01;26(34):5500-1 PMID: 18936468 SCOPUS ID: 2-s2.0-57149105935 10/22/2008       10 Citations
  • Clinical outcomes of patients receiving integrated PET/CT-guided radiotherapy for head and neck carcinoma. (Vernon MR, Maheshwari M, Schultz CJ, Michel MA, Wong SJ, Campbell BH, Massey BL, Wilson JF, Wang D) Int J Radiat Oncol Biol Phys 2008 Mar 01;70(3):678-84 PMID: 18262086 SCOPUS ID: 2-s2.0-38849083351 02/12/2008       83 Citations
  • Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911. (Langer CJ, Harris J, Horwitz EM, Nicolaou N, Kies M, Curran W, Wong S, Ang K) J Clin Oncol 2007 Oct 20;25(30):4800-5 PMID: 17947728 SCOPUS ID: 2-s2.0-36049015455 10/20/2007       316 Citations
  • Strategic plans to promote head and neck cancer translational research within the radiation therapy oncology group: a report from the translational research program. (Chung CH, Wong S, Ang KK, Hammond EH, Dicker AP, Harari PM, Le QT) Int J Radiat Oncol Biol Phys 2007;69(2 Suppl):S67-78 PMID: 17848300 PMCID: PMC2064008 SCOPUS ID: 2-s2.0-34548476013 10/18/2007       11 Citations
  • Oxaliplatin hypersensitivity: case report and successful repeat desensitization. (Edmondson DA, Gruling BJ, Urmanski AM, Wong SJ, Levy MB) Am J Ther 2007;14(1):116-8 PMID: 17303980 SCOPUS ID: 2-s2.0-33847169070 02/17/2007       21 Citations
  • Locally recurrent, previously irradiated head and neck cancer: concurrent re-irradiation and chemotherapy, or chemotherapy alone? (Wong SJ, Machtay M, Li Y) J Clin Oncol 2006 Jun 10;24(17):2653-8 PMID: 16763279 SCOPUS ID: 2-s2.0-33748177338 06/10/2006       119 Citations
  • A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer. (Argiris A, Cohen E, Karrison T, Esparaz B, Mauer A, Ansari R, Wong S, Lu Y, Pins M, Dancey J, Vokes E) Cancer Biol Ther 2006 Jul;5(7):766-70 PMID: 16760642 SCOPUS ID: 2-s2.0-33751184394 06/09/2006       108 Citations
  • Initial experience of FDG-PET/CT guided IMRT of head-and-neck carcinoma. (Wang D, Schultz CJ, Jursinic PA, Bialkowski M, Zhu XR, Brown WD, Rand SD, Michel MA, Campbell BH, Wong S, Li XA, Wilson JF) Int J Radiat Oncol Biol Phys 2006 May 01;65(1):143-51 PMID: 16618577 SCOPUS ID: 2-s2.0-33645964284 04/19/2006       129 Citations
  • Reversible posterior leukoencephalopathy syndrome and bevacizumab [21] (Ozcan C, Wong SJ, Hari P) New England Journal of Medicine 2 March 2006;354(9):981-982 SCOPUS ID: 2-s2.0-33644599473 03/02/2006       73 Citations
  • Inhibition of malignant cell growth by 311, a novel iron chelator of the pyridoxal isonicotinoyl hydrazone class: effect on the R2 subunit of ribonucleotide reductase. (Green DA, Antholine WE, Wong SJ, Richardson DR, Chitambar CR) Clin Cancer Res 2001 Nov;7(11):3574-9 PMID: 11705879 SCOPUS ID: 2-s2.0-0035181433 11/14/2001       98 Citations
  • Increased sensitivity of hydroxyurea-resistant leukemic cells to gemcitabine. (Wong SJ, Myette MS, Wereley JP, Chitambar CR) Clin Cancer Res 1999 Feb;5(2):439-43 PMID: 10037195 SCOPUS ID: 2-s2.0-0032972705 02/26/1999       20 Citations
    • Last update: 11/12/2025